



#6 P3
10/10/02

Patent
Attorney's Docket No. 017753-137

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
Etienne REGULIER <i>et al.</i>)	Group Art Unit: 1632
Application No.: 09/762,573)	Examiner: Liping Chen
Filed: February 8, 2001)	Confirmation No.: 5075
For: COMPOSITION FOR)	
IMPLEMENTING A CYTOTOXIC, IN)	
PARTICULAR AN ANTITUMORAL OR)	
ANTIVIRAL TREATMENT IN A MAMMAL)	

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Response to Restriction Requirement is in complete response to the Official Action (Restriction Requirement) mailed on August 5, 2002 (Paper No. 4). A one-month Extension of Time is filed herewith, extending the due date to October 7, 2002 (October 5, 2002 falls on a Saturday).

The Examiner has required the election of a single Group, pursuant to PCT Rule 13.1. Applicants hereby elect, with traverse, Group II (*i.e.*, claims 1-21, and 24-47), drawn to drawn to a composition comprising a) a nucleic acid sequence encoding all or part of an MIP chemokine and b) at least one nucleic acid sequence encoding all or part of a cytokine having at least cytotoxic activity, a vector, a formulation, and a method of treating a patient in need.

With regard to a species, Applicants hereby elect, with traverse, interleukin-2 (IL-2), for purposes of examination.

RECEIVED

OCT 10 2002

TECH CENTER 1600/2900